Major US Eye Drop Recall Over Sterility Concerns
More than three million bottles of over-the-counter eye drops have been recalled across the United States due to fears they could be contaminated and potentially harm vision. The manufacturer, K.C. Pharmaceuticals based in California, issued the alert for its generic eye drop products, citing a "lack of assurance of sterility" as the primary reason for the action.
FDA Classification and Product Details
The US Food and Drug Administration (FDA) has classified this as a Class II recall, indicating a temporary and reversible risk to eyes and vision if the products are used. While it remains unclear whether any bottles are actually contaminated, the precautionary measure affects eye drops sold in 0.5 fluid ounce bottles with best-before dates extending to May or October of this year.
These products were widely available at major retailers including CVS, Walgreens, Kroger, and H-E-B, among other stores nationwide. The recall encompasses eight different product lines with specific quantities:
- 1 million bottles of Dry Eye Relief Eye Drops
- 590,000 bottles of Artificial Tears Sterile Lubricant Eye Drops
- 378,000 bottles of Sterile Eye Drops Original Formula
- 315,000 bottles of Sterile Eye Drops Redness Lubricant
- 303,000 bottles of Eye Drops Advanced Relief
- 245,000 bottles of Ultra Lubricating Eye Drops
- 182,000 bottles of Sterile Eye Drops AC
- 74,000 bottles of Sterile Eye Drops Soothing Tears
Recall Process and Consumer Guidance
The recall was initiated on March 3, 2024, and received its FDA classification on March 31. The issue was revealed through an Enforcement Report on the FDA website, though no formal press release has been issued. While no illnesses or injuries have been reported to date in connection with this recall, consumers are typically advised not to use the products and to either discard them immediately or return them to sellers for a full refund.
The lot codes for affected products are available on the FDA website for verification. The "lack of assurance of sterility" suggests potential contamination with bacteria or particles that could damage the eye, possibly stemming from improper hygiene standards at the manufacturing facility.
Historical Context and Health Implications
This recall follows a significant 2023 eye drop recall involving products manufactured in India that were contaminated with Pseudomonas aeruginosa, a bacteria resistant to standard antibiotics. That incident resulted in 81 patients becoming ill, with 18 suffering permanent blindness and four fatalities. The bacteria can infect the eye, leading to vision loss, and in severe cases, spread to the bloodstream causing potentially fatal sepsis.
In a separate incident earlier this year, Imprimis NJOF recalled nearly 2,000 boxes of prefilled syringes for treating eye infections due to the presence of "glass-like particles."
Symptoms and Medical Advice
Medical professionals warn that warning signs of complications from eye drops include:
- Persistent redness
- Eye pain
- Abnormal yellow discharge
- Increased light sensitivity
- Blurred vision
Doctors emphasize that anyone experiencing these symptoms or concerned about potential ill effects from the recalled eye drops should contact their healthcare provider immediately. This is particularly urgent for those experiencing sudden, severe, or persistent eye pain, or sudden, significant changes in vision.
With more than a third of Americans estimated to use over-the-counter eye drops or eyewash products—typically for lubricating dry eyes, reducing redness, or soothing irritation from environmental contaminants like smoke particles—this recall affects a substantial portion of the population. Consumers are urged to check their medicine cabinets and take appropriate action if they possess any of the affected products.
